Abercrombie pops on reports that American Eagle is working on a buyout bid >>> READ MORE

6 Pharmaceutical Stocks to Sell Now

WCRX, HITK, OPTR, AVNR, PTX, HZNP slump in weekly rankings


For the current week, the overall ratings of six Pharmaceutical stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Warner Chilcott (NASDAQ:WCRX) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Warner Chilcott engages in the development, manufacture, and promotion of branded pharmaceutical products focusing on the women’s healthcare, gastroenterology, dermatology, and urology markets in North America and western Europe. The price of WCRX is down 21.9% from a month ago. This is worse than the Nasdaq’s 2.1% increase for the same period. For more information, get Portfolio Grader’s complete analysis of WCRX stock.

This is a rough week for Hi-Tech Pharmacal (NASDAQ:HITK). The company’s rating falls to D from the previous week’s C. Hi-Tech Pharmacal manufactures prescription and over-the-counter generic and branded pharmaceuticals in liquid and semi-solid dosage forms. The stock gets F’s in Earnings Revisions and Earnings Surprise. The stock price has fallen 6.9% over the past month. For a full analysis of HITK stock, visit Portfolio Grader.

Optimer Pharmaceuticals‘s (NASDAQ:OPTR) rating weakens this week, dropping to a D versus last week’s C. Optimer Pharmaceuticals discovers, develops, and commercializes anti infective products. The stock also gets an F in Equity. Investors seem to agree with the downgrade and have pushed down the share price 5.7% over the past month. As of Sept. 28, 2012, 20.2% of outstanding Optimer Pharmaceuticals shares were held short. To get an in-depth look at OPTR, get Portfolio Grader’s complete analysis of OPTR stock.

This week, Avanir Pharmaceutical (NASDAQ:AVNR) drops from a C to a D rating. Avanir Pharmaceuticals engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. The stock gets F’s in Equity and Cash Flow. As of Sept. 28, 2012, 15% of outstanding Avanir Pharmaceutical shares were held short. For a full analysis of AVNR stock, visit Portfolio Grader.

Pernix Therapeutics Holdings (AMEX:PTX) earns a F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Pernix Therapeutics Holdings acquires, develops, and markets medications for the pediatric market. The stock gets F’s in Earnings Growth, Earnings Momentum, and Sales Growth. The trailing PE Ratio for the stock is 31.10. For more information, get Portfolio Grader’s complete analysis of PTX stock.

This week, Horizon Pharma Inc.‘s (NASDAQ:HZNP) rating worsens to a D from the company’s C rating a week ago. Horizon Pharma, Inc is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The stock gets F’s in Equity and Cash Flow. Share prices fell 17.8% over the past month. As of Sept. 28, 2012, 16.7% of outstanding Horizon Pharma Inc. shares were held short. For a full analysis of HZNP stock, visit Portfolio Grader.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.

Article printed from InvestorPlace Media, http://investorplace.com/2012/09/6-pharmaceutical-stocks-to-sell-now-wcrx-hitk-optr/.

©2017 InvestorPlace Media, LLC